IGM Biosciences, Inc. IGMS
At closeAug 14, 2025, 4:00 PM EDT
- YTD
- -79.21%
- 1 year
- -85.70%
- Market cap
- 77.50M
- Revenue (ttm)
- 2.92M
- EPS (ttm)
- -0.90
- Shares out
- 34.08M
- Forward P/E
- -2.71
- YTD return
- -79.21%
- 1-year return
- -85.70%
- Volume
- 1.59M
- Avg volume
- 480.75K
- Open
- 1.27
- Previous close
- 1.27
- Day's range
- 1.27 – 1.27
- 52-week range
- 0.92 – 22.50
- Beta
- 0.19
- Analysts
- Buy
- Price target
- 19.73 (+1453.3%)
- Earnings date
- Aug 14, 2024
2Y -6.09 (-82.74%)
Key statistics
- Enterprise value
- 237.37M
- PEG ratio
- 0.00
- Price / sales
- 132.66
- Price / book
- 4.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1.40%
- Free cash flow
- -100.20M
- Total cash
- 218.79M
- Total debt
- 45.86M
- Return on equity
- -132.11%
- Short % of float
- 17.77%
- 50-day average
- 12.15
- 200-day average
- 10.57
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 19.73
- Target (high)
- 48.00
- Strong buy2
- Buy4
- Hold4
- Sell0
- Strong sell1
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.785.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.82 | -1.01 | -0.19 | -23.17% |
| Aug 14, 2024 | Jun 1, 2024 | 0.03 | -0.79 | -0.82 | -2,733.33% |
| Aug 14, 2024 | Jun 1, 2024 | 0.03 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.84 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.84 | -0.83 | +0.01 | +1.19% |
| Mar 7, 2024 | Dec 1, 2023 | -1.06 | -1.01 | +0.05 | +4.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | BMO Capital | init | — | Outperform |
| Nov 11, 2024 | Stifel | main | Buy | Buy |
| Oct 18, 2024 | RBC Capital | main | Outperform | Outperform |
| Oct 1, 2024 | Guggenheim | main | Buy | Buy |
| Oct 1, 2024 | Wedbush | main | Outperform | Outperform |
| Oct 1, 2024 | RBC Capital | main | Outperform | Outperform |
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- igmbio.com
News
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates 
IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders 
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right 
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates 
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release 
Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Your note
Sign in to keep a note on IGMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 29, 2024 | 0 |
| BEHRENS M KATHLEEN | Director | Stock Award(Grant) | Sep 29, 2024 | 406,515 |
| DECKER LISA LYNN | Officer | Sale | Dec 15, 2024 | 78,041 |
| HARLER MARY BETH | Chief Executive Officer | Sale | Dec 15, 2024 | 347,032 |
| LEE MICHAEL STEWART | Director | Stock Award(Grant) | Sep 29, 2024 | 9,322 |
| REDMILE GROUP, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 29, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 12.01% | 4,092,310 | 26.64M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 11.78% | 4,014,259 | 26.13M | Sep 29, 2024 |
| Siren, L.L.C. | 9.77% | 3,330,422 | 21.68M | Sep 29, 2024 |
| Redmile Group, LLC | 9.02% | 3,072,478 | 20.00M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 3.70% | 1,259,230 | 8.20M | Sep 29, 2024 |
| Blackrock Inc. | 2.64% | 899,921 | 5.86M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 5.77% | 1,966,446 | 12.80M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 2.49% | 849,754 | 5.53M | Sep 29, 2024 |
| Fidelity Select Portfolios - Biotechnology | 2.38% | 809,982 | 5.27M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.35% | 461,049 | 3.00M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.18% | 401,289 | 2.61M | Oct 30, 2024 |
| Price (T.Rowe) New Horizons Trust | 1.16% | 396,148 | 2.58M | Sep 29, 2024 |